Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

被引：2
|
作者：
Desai, Jayesh
Voskoboynik, Mark
Markman, Ben
Hou, Jeannie
Zeng, Dewan
Meniawy, Tarek
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Nucleus Network, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Monash Univ, Melbourne, Vic, Australia
[6] BeiGene USA Inc, Emeryville, CA USA
[7] Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS3113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3113
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types
    Kotsakis, Athanasios
    Georgoulias, Vassilis
    LANCET ONCOLOGY, 2017, 18 (05): : 556 - 557
  • [42] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Moindrot, Nicolas
    Larois, Christelle
    Classe, Marion
    Sidhu, Sukhvinder
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Safety, antitumor activity and biomarker of anti-PD-1 antibody in patients with advanced esophageal carcinoma.
    Meng, Xiangrui
    Meng, Yachao
    Wang, Feng
    Fan, Qing Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
    Mehnert, Janice M.
    Varga, Andrea
    Brose, Marcia S.
    Aggarwal, Rahul R.
    Lin, Chia-Chi
    Prawira, Amy
    de Braud, Filippo
    Tamura, Kenji
    Doi, Toshihiko
    Piha-Paul, Sarina A.
    Gilbert, Jill
    Saraf, Sanatan
    Thanigaimani, Pradeep
    Cheng, Jonathan D.
    Keam, Bhumsuk
    BMC CANCER, 2019, 19 (1)
  • [45] Open-label, phase I, dose escalation/expansion trial of the anti-SIRPa monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
    Gutierrez, M.
    Jamal, R.
    Yamamoto, N.
    Doi, T.
    Elgadi, M.
    Ferrada, J. L.
    Wojciekowski, S. M.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S485 - S485
  • [46] AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
    Wu, Lingying
    Wang, Peng-Hui
    Hsiao, Sheng-Yen
    Chang, Chih-Long
    Kim, Hee Seung
    Lee, Jung-Yun
    Ryu, Sang-Young
    Zuo, Yunxia
    Mu, Xiyan
    Gao, Yujuan
    Yang, Silu
    Lee, Jae-Kwan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.
    Hyman, David Michael
    Brana, Irene
    Spreafico, Anna
    Schram, Alison M.
    Pandya, Naimish B.
    Hoffman, Kimberly
    Hallet, Robin
    Giblin, Patricia
    Anido, Judit
    Ruano, Isabel Huber
    Wasserman, Robert
    Magram, Jeanne
    Siu, Lillian L.
    Tabernero, Josep
    Seoane, Joan
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors
    Moerk, S. K.
    Donia, M.
    Kringelum, J. V.
    Bogenrieder, T.
    Rono, B.
    Sorensen, A. B.
    Draghi, A.
    Bol, K. F.
    Petersen, N. V.
    Kadivar, M.
    Hernandez, S. S.
    Hadrup, S. Reker
    Andreasen, L. V.
    Christensen, D.
    Andersen, P. L.
    Svane, I. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 41 - 41
  • [49] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
    Oaknin, A.
    Tinker, A. V.
    Gilbert, L.
    Samouelian, V.
    Mathews, C. A.
    Brown, J.
    Guo, W.
    Danaee, H.
    Im, E.
    Sabatier, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 6 - 6
  • [50] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
12345